IMAGING CENTRAL SEROTONIN RECEPTORS (5HT2) WITH C MDL 100907--PETT SCAN

使用 C MDL 100907--PETT 扫描对中枢血清素受体 (5HT2) 进行成像

• 批准号: 6114359
• 负责人: Dean Foster Wong
• 金额: $ 2.06万
• 依托单位: JOHNS HOPKINS UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6114359
• 关键词: amphetamines; dopamine receptor; human subject; positron emission tomography; receptor expression; reserpine; serotonin receptor; stimulant /agonist

To measure the effect of DAe and the DA surge on the quantitation of DA receptor density using NMSP and RAC. Using amphetamine (AMP) and reserpine (RES), which, respectively, increases or decreases DAe, we will perturb the DA system. We will then measure the effects of these perturbations on DA D2 receptors ("D2-like"). Progress is to examine the effects of endogenous dopamine on the quantification of absolute receptor density Bmax with [11C]raclopride and [11C]NMSP. To date, we have successfully completed eight normal subjects and four schizophrenic patients with two measurements of Bmax without and with amphetamine. Since each Bmax measurement requires both high and low specific activity [11C]raclopride, each subject received four PET scans over a period of 1-2 weeks. This is logistically a complex procedure, since in the case of the patients, they must remain drug-free between the pairs of PET scans, each pair of which are carried out on a single day. This has often required hospitalization in the Clinical Research Unit at Johns Hopkins. In some cases, for clinical reasons, it has been necessary to enter subjects into a two PET scan protocol only, with two high specific activity [11C]raclopride studies without and with amphetamine during the same day. This has occurred in one of the six patients recruited so far. The effect of amphetamine is to cause a fall in the observed Bmax. The average fall in Bmax is greater in schizophrenic patients (2 to 3 fold) but the variance is very large in patients and normals. With methods refinement, more subtyping and expanded samples these results may achieve statistical significance.

测量 DAe 和 DA 激增对 DA 定量的影响 使用 NMSP 和 RAC 的受体密度。 使用安非他明 (AMP) 和 利血平 (RES)，分别增加或减少 DAe，我们 会干扰 DA 系统。然后我们将衡量这些影响 对 DA D2 受体（“D2 样”）的干扰。 进展是检查内源性多巴胺对 [11C]雷氯必利绝对受体密度 Bmax 的定量 和[11C]NMSP。 迄今为止，我们已顺利完成八项正常工作 受试者和四名精神分裂症患者进行了两次 Bmax 测量 不含和含有安非他明。 由于每次 Bmax 测量都需要 高和低比活性[11C]雷氯必利，每个受试者接受 1-2 周内进行四次 PET 扫描。 这在逻辑上是一个 程序复杂，因为就患者而言，他们必须保持 每对 PET 扫描之间均不含药物 一天出去。 这通常需要住院治疗 约翰·霍普金斯大学临床研究单位。 在某些情况下，为了临床 由于原因，有必要让受试者接受两次 PET 扫描 仅方案，有两项高比活性 [11C]雷氯必利研究 在同一天不使用和使用安非他明。 这发生在 迄今为止招募的六名患者之一。 安非他明的作用是导致观察到的 Bmax 下降。 这 精神分裂症患者的 Bmax 平均下降幅度更大（2 至 3 倍） 但患者和正常人之间的差异非常大。 有方法 细化、更多子类型和扩展样本这些结果可能 达到统计显着性。